Compare JPMorgan Chase & Co (JPM) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Medpace Holdings Inc — how do they compare? JPMorgan Chase & Co trades at $339.1 (market cap $900.78B), while Medpace Holdings Inc trades at $519.93 (market cap $15.08B). The key difference: JPMorgan Chase & Co is far larger — about 59.7× Medpace Holdings Inc's market cap, and JPMorgan Chase & Co pays a 1.77% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| JPM | MEDP | |
|---|---|---|
Market Cap | $900.78B | $15.08B |
Volume | 10,479,943 | — |
Sector | Financials | Technology |
52-Week High | $346.91 | $620.59 |
52-Week Low | $282.84 | $308.88 |
Dividend Yield | 1.77% | — |
Enterprise Value | — | $14.55B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase trades at $341.10, down 0.6% on the day, with a bullish technical signal from moving averages and support at $339. The company reported strong Q1 and Q2 2026 earnings beats, with revenue growth from $169.4B in 2024 to $181.8B in 2025. Analyst consensus is Moderate Buy with a $374 price target, representing 9.6% upside potential. Recent news highlights CEO Jamie Dimon's economic warnings and upcoming Q1 earnings on April 14.
JPMorgan demonstrates solid fundamentals with consistent revenue growth and strong net income margins above 30%. The stock appears reasonably valued with a P/E of 14.6. Key risks include geopolitical tensions impacting banking operations and cybersecurity vulnerabilities from advanced AI systems. The bullish analyst sentiment and technical setup suggest potential for continued upside if earnings momentum persists.
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
